Sign in
TerminatedNo phase

Oxygen Therapy in Patients With Chronic Heart Failure With Reduced Ejection Fraction

Key facts

Who runs it
Institut d'Investigació Biomèdica de Girona Dr. Josep Trueta
Where
Spain1 site in 1 countryChoose a country to see its sites
Trial code
Status
Terminated
People taking part
1 person enrolled
Started
1 Jul 2022
Ended
31 Jul 2024
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Oxygen Therapy
Record updated
8 October 2024
Why it stopped
Difficulty in recruitment

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part
Show the full registry criteria (10)Hide the full registry criteria

Who can take part

  • Patients > 18 years old
  • Diagnosis and clinic of chronic heart failure with ventricular dysfunction with left ventricular ejection fraction (LVEF) <40% under optimal medical treatment regardless of its etiology and having presented at least one episode of decompensation (visits to the emergency room, hospitalizations and/or need for intravenous depletive treatment) during the last year
  • Nocturnal desaturation defined as mean SatO2 <90% and/or Cummulative time (TC) <90>22 minutes to nocturnal pulse oximetry done at home
  • Signed informed consent

Who cannot take part

  • Previous treatment with oxygen therapy
  • Chronic lung disease (includes chronic obstructive pulmonary disease with Pulmonary respiratory function (PRF) (forced expiratory volume at one second/forced vital capacity (FEV1/FVC) <70%), diffuse interstitial diseases, pulmonary hypertension of respiratory)
  • Obstructive sleep apnea-hypopnea syndrome (OSAHS) with Apnea hypopnea index (AHI) > 14.9
  • Not agreeing to attend periodic cardiology visits
  • Being part of other clinical studies that contraindicate an intervention
  • Pregnant or breastfeeding women

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

The purpose of this study is to assess patients with chronic heart failure and moderate-severe ventricular dysfunction (left ventricular ejection fraction (FEVE) <40%) with nocturnal desaturation (mean Oxygen saturation (SatO2) <90% and/or Cummulative time (TC) <90% > 22 minutes) without underlying respiratory disease, oxygen treatment during hours of night rest will reduce exacerbations, improve the ability to effort, sleep quality and poor prognostic parameters of heart failure, compared to patients not receiving oxygen treatment.

The 2 groups in the trial

  • Oxygen TherapyExisting treatment, for comparison

    Participants received nocturnal oxygen therapy (minimum 6 hours) for 6 months.

  • No Oxygen TherapyNo study treatment, for comparison

    Participants will not received oxygen therapy

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Impact of Oxygen Therapy on Readmissions of Patients With Chronic Heart Failure With Reduced Ejection Fraction
Record updated
8 October 2024